115467-08-8

Basic information

• Product Name: 4-BROMO-1-ETHOXY-2-FLUOROBENZENE
• Synonyms: 4-BROMO-1-ETHOXY-2-FLUOROBENZENE;4-Bromo-2-fluoroethoxybenzene;4-Bromo-2-fluorophenetole
• CAS NO: 115467-08-8
• Molecular Formula: C₈H₈BrFO
• Molecular Weight: 219.06
• Mol File: 115467-08-8.mol

Chemical Properties

• Boiling Point: 233.4±20.0 °C(Predicted)
• Appearance: /
• Density: 1.457±0.06 g/cm3(Predicted)
• CAS DataBase Reference: 4-BROMO-1-ETHOXY-2-FLUOROBENZENE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-BROMO-1-ETHOXY-2-FLUOROBENZENE(115467-08-8)
• EPA Substance Registry System: 4-BROMO-1-ETHOXY-2-FLUOROBENZENE(115467-08-8)

Safety Data

• Hazardous Substances Data: 115467-08-8(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
4-BROMO-1-ETHOXY-2-FLUOROBENZENE is used as a building block for the synthesis of more complex organic molecules. Its unique structure allows for various chemical reactions, making it a valuable component in the creation of new compounds.
Used in Pharmaceutical Research:
In the pharmaceutical industry, 4-BROMO-1-ETHOXY-2-FLUOROBENZENE is used as a starting material for the development of new drugs. Its presence in the molecular structure can influence the properties and effectiveness of the final drug product, making it an important component in drug discovery and design.
Used in Chemical Research:
4-BROMO-1-ETHOXY-2-FLUOROBENZENE is also used in academic and industrial research settings to study the properties and reactions of halogenated aromatic compounds. Understanding the behavior of such compounds can lead to advancements in various fields, including materials science and catalysis.

Upstream product

• 2105-94-4 4-bromo-2-fluorophenol 
• 75-03-6 ethyl iodide 
• 367-12-4 2-fluorophenol 
• 74-96-4 ethyl bromide 

Downstream Products

• 279263-10-4 (4-ethoxy-3-fluorophenyl)boronic acid 
• 871126-14-6 (6-bromo-3-ethoxy-2-fluorophenyl)boronic acid 
• 1114809-07-2 6-bromo-3-ethoxy-2-fluorobenzaldehyde 
• 98121-48-3 4-ethoxy-3-fluorophenol 
• 868562-02-1 C₁₅H₁₁Br₂F₃O₂ 
• 909416-50-8 1-cyclopentyl-3-(4-ethoxy-3-fluoro-phenyl)-propan-1-one 
• 5710-64-5 4-ethoxy-3-fluorobenzoic acid 

Relevant articles and documents

LIQUID CRYSTALLINE COMPOUND HAVING NEGATIVE DIELECTRIC ANISOTROPY HAVING FLUOROBIPHENYL, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY ELEMENT

PROBLEM TO BE SOLVED: To provide a liquid crystalline compound exhibiting high stability against heat or light, high clearing point (or high upper limit temperature), low lower limit temperature of a liquid crystal phase, low viscosity, appropriate optical anisotropy, negative large dielectric constant anisotropy, appropriate elastic modulus, and excellent compatibility with other liquid crystalline compounds at a room temperature or a low temperature, and to provide a liquid crystal composition containing the compound and a liquid crystal display element containing the composition. SOLUTION: There is provided a compound represented by the formula (1). R1 is alkyl having 2 to 10 carbon atoms, in which one -CH2CH2- is substituted by -CH=CH-, or the like; R2 is alkyl having 1 to 8 carbon atoms, a ring A1 is 1,4-cyclohexylene or the like, Y1 and Y2 are hydrogen, fluorine or the like, Z1 is a single bond or the like; n1 is 1 or 2. SELECTED DRAWING: None COPYRIGHT: (C)2019,JPOandINPIT

New pyrrolidine derivatives, pharmaceutical compositions and uses thereof

Pyrrolidine derivatives of the formula and their use as medicaments for the treatment of obesity and type 2 diabetes.

LIQUID CRYSTALLINE COMPOUND WITH NEGATIVE DIELECTRIC ANISOTROPY, LIQUID CRYSTAL COMPOSITION USING SAME, AND LIQUID CRYSTAL DISPLAY ELEMENT

The invention provides a liquid crystal compound having general physical properties necessary for the liquid crystal compound, namely, stability to heat, light and so forth, a small viscosity, a refractive index anisotropy having a suitable magnitude value, a dielectric anisotropy having a suitable magnitude value, steep electrooptical characteristics, a wide temperature range of a nematic phase, and an excellent compatibility with other liquid crystal compounds, in particular, a liquid crystal compound having a wide temperature range of the nematic phase; a compound represented by formula (i): wherein, for example, R1 and R2 are alkyl having 1 to 8 carbons or alkenyl having 2 to 8 carbons; ring A1 is trans-1,4-cyclohexylene or 1,4-phenylene; ring A2 is trans-1,4-cyclohexylene or 2,3-difluoro-1,4-phenylene; Q1 and Q2 are fluorine or chlorine; and h is 0, 1 or 2.

CYANOCYCLOPROPYLCARBOXAMIDES AS CATHEPSIN INHIBITORS

The present invention relates to compounds of formula (I) for treating diseases associated with cysteine protease activity. The compounds are reversible inhibitors of cysteine proteases, including cathepsins B, K, C, F, H, L, O, S, W and X. Of particular interest are diseases associated with Cathepsin K.

BENZOCHROMENE DERIVATIVES

The invention relates to benzochromene derivatives of formula (I), in which the different parameters have the meanings as cited in the text, to liquid crystal media, which contain these compounds, and to the use of these media in electro-optical displays,

Potent, novel in vitro inhibitors of the Pseudomonas aeruginosa deacetylase LpxC

Deacetylation of uridyldiphospho-3-O-(R-hydroxydecanoyl)-N-acetylglucosamine by LpxC is the first committed step in the Pseudomonas aeruginosa biosynthetic pathway to lipid A; homologous enzymes are found widely among Gram-negative bacteria. As an essential enzyme for which no inhibitors have yet been reported, the P. aeruginosa LpxC represents a highly attractive target for a novel antibacterial drug. We synthesized several focused small-molecule libraries, each composed of a variable aromatic ring, one of four heterocyclic/spacer moieties, and a hydroxamic acid and evaluated the LpxC inhibition of these compounds against purified P. aeruginosa enzyme. To ensure that the in vitro assay would be as physiologically relevant as possible, we synthesized a tritiated form of the specific P. aeruginosa glycolipid substrate and measured directly the enzymatically released acetate. Several of our novel compounds, predominantly those having fluorinated substituents on the aromatic ring and an oxazoline as the heterocyclic moiety, demonstrated in vitro IC50 values less than 1 μM. We now report the synthesis and in vitro evaluation of these P. aeruginosa LpxC inhibitors.

Insecticidal ethers

This invention relates to novel fluorinated ethers, useful as insecticides and acaricides, to processes and intermediates for their preparation, to insecticidal and acaricidal compositions thereof and to methods of combating and controlling insect and acarine pests therewith.

Diphenyl ether derivatives and their use as insecticides

A compound of formula: STR1 wherein W represents one or more substituents selected from halo, alkyl, alkoxy, alkoxyalkyl, haloalkyl and haloalkoxy or W represents a bidentate group linking adjacent carbon atoms selected from alkylene and alkylenedioxy; Y is a group of formula STR2 wherein X is a group of formula --(CF2)n R3, where R3 is selected from hydrogen, chloro and fluoro, and n is one or two, R1 is selected from hydrogen, chloro, fluoro and hydroxy and R2 is selected from methyl, cyano, ethynyl and hydrogen; Q is selected from carbon bearing a hydrogen atom and nitrogen; and Z represents one or more substituents selected from fluoro, benzyl, phenoxy, chlorophenoxy, fluorophenoxy and bromophenoxy, or any isomer thereof. Processes for preparing these compounds and intermediates for use therein, insecticidal compositions containing these compounds and the use thereof are also disclosed.